Literature DB >> 2794044

Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E. A preliminary report.

S B Sinclair1, P D Greig, L M Blendis, M Abecassis, E A Roberts, M J Phillips, R Cameron, G A Levy.   

Abstract

The effect of PG on patients with fulminant and subfulminant viral hepatitis (FHF) was studied. 17 patients presented with FHF secondary to hepatitis A (n = 3), hepatitis B (n = 6), and non-A, non-B (NANB) hepatitis (n = 8). 14 of the 17 patients had stage III or IV hepatic encephalopathy (HE). At presentation the mean aspartate transaminase (AST) was 1,844 +/- 1,246 U/liter, bilirubin 232 +/- 135 mumol/liter, prothrombin time (PT) 34 +/- 18, partial thromboplastin time (PTT) 73 +/- 26 s, and coagulation Factors V and VII 8 +/- 4 and 9 +/- 5%, respectively. Intravenous PGE1 was initiated 24-48 h later after a rise in AST (2,195 +/- 1,810), bilirubin (341 +/- 148), PT (36 +/- 15), and PTT (75 +/- 18). 12 of 17 responded rapidly with a decrease in AST from 1,540 +/- 833 to 188 +/- 324 U/liter. Improvement in hepatic synthetic function was indicated by a decrease in PT from 27 +/- 7 to 12 +/- 1 s and PTT from 61 +/- 10 to 31 +/- 2 s, and an increase in Factor V from 9 +/- 4 to 69 +/- 18% and Factor VII from 11 +/- 5 to 71 +/- 20%. Five responders with NANB hepatitis relapsed upon discontinuation of therapy, with recurrence of HE and increases in AST and PT, and improvement was observed upon retreatment. After 4 wk of intravenous therapy oral PGE2 was substituted. Two patients with NANB hepatitis recovered completely and remained in remission 6 and 12 mo after cessation of therapy. Two additional patients continued in remission after 2 and 6 mo of PGE2. No relapses were seen in the patients with hepatitis A virus and hepatitis B virus infection. Liver biopsies in all 12 surviving patients returned to normal. In the five nonresponders an improvement in hepatic function was indicated by a fall in AST (3,767 +/- 2,611 to 2,142 +/- 2,040 U/liter), PT (52 +/- 25 to 33 +/- 18 s), and PTT (103 +/- 29 to 77 +/- 44 s), but all deteriorated and died of cerebral edema (n = 3) or underwent liver transplantation (n = 2). These results suggest efficacy of PGE for FHF, and further investigation is warranted.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2794044      PMCID: PMC329761          DOI: 10.1172/JCI114268

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

1.  Hepatits A virus infection in fulminant hepatitis and chronic active hepatitis.

Authors:  J Rakela; A G Redeker; V M Edwards; R Decker; L R Overby; J W Mosley
Journal:  Gastroenterology       Date:  1978-05       Impact factor: 22.682

2.  Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy.

Authors:  H O Conn
Journal:  Am J Dig Dis       Date:  1977-06

3.  Charcoal hemoperfusion. Plus ça change, plus c'est la même chose.

Authors:  P D Berk; J D Goldberg
Journal:  Gastroenterology       Date:  1988-05       Impact factor: 22.682

4.  Orthotopic liver transplantation for fulminant and subacute hepatic failure.

Authors:  A C Stieber; G Ambrosino; D Van Thiel; S Iwatsuki; T E Starzl
Journal:  Gastroenterol Clin North Am       Date:  1988-03       Impact factor: 3.806

Review 5.  Modulation of inflammation and immunity by cyclic AMP.

Authors:  H R Bourne; L M Lichtenstein; K L Melmon; C S Henney; Y Weinstein; G M Shearer
Journal:  Science       Date:  1974-04-05       Impact factor: 47.728

6.  Species differences in hepatic glutathione depletion, covalent binding and hepatic necrosis after acetaminophen.

Authors:  D C Davis; W Z Potter; D J Jollow; J R Mitchell
Journal:  Life Sci       Date:  1974-06-01       Impact factor: 5.037

7.  Prostaglandin E2 prevents fulminant hepatitis and the induction of procoagulant activity in susceptible animals.

Authors:  M Abecassis; J Falk; V Dindzans; W Lopatin; L Makowka; G Levy; R Falk
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

8.  Causes of death in fulminant hepatic failure and relationship to quantitative histological assessment of parenchymal damage.

Authors:  B G Gazzard; B Portmann; I M Murray-Lyon; R Williams
Journal:  Q J Med       Date:  1975-10

9.  Expression of class I and class II major histocompatibility complex antigens on human hepatocytes.

Authors:  A Franco; V Barnaba; P Natali; C Balsano; A Musca; F Balsano
Journal:  Hepatology       Date:  1988 May-Jun       Impact factor: 17.425

10.  Vigorous medical management of acute fulminant hepatitis.

Authors:  M O Auslander; G L Gitnick
Journal:  Arch Intern Med       Date:  1977-05
View more
  27 in total

1.  Protective effects of prostaglandin E1 on hepatocytes.

Authors:  Xian-Ling Liu; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

2.  Liver transplantation for alcoholic liver disease, viral hepatitis, and hepatic neoplasms.

Authors:  D H Van Thiel; B Carr; S Iwatsuki; A Tzakis; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1991-06       Impact factor: 1.066

3.  Beneficial effects of administering intraportal prostaglandin E1 postoperatively to hepatectomy patients with massive intraoperative blood loss.

Authors:  T Katsuramaki; M Mukaiya; K Yamashiro; H Kimura; R Denno; K Hirata
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

4.  Fulminant hepatitis--is the survival improving?

Authors:  Y Muto
Journal:  Gastroenterol Jpn       Date:  1992-02

Review 5.  Smoking, the oral contraceptive pill, and Crohn's disease.

Authors:  A J Wakefield; A M Sawyerr; M Hudson; A P Dhillon; R E Pounder
Journal:  Dig Dis Sci       Date:  1991-08       Impact factor: 3.199

Review 6.  Renal dysfunction associated with liver transplantation.

Authors:  R M Jindal; I Popescu
Journal:  Postgrad Med J       Date:  1995-09       Impact factor: 2.401

Review 7.  Hepatic disorders. Features and appropriate management.

Authors:  M A Aldersley; J G O'Grady
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

8.  Preventative effect of PGE1 for postoperative liver damage.

Authors:  N Iwatsuki; A Yasuda; S Tokutomi; T Saishu; Y Koga; Y Hashimoto
Journal:  J Anesth       Date:  1992-04       Impact factor: 2.078

9.  Intra-operative blood pressure control by prostaglandin E1 in patients with hypertension and ischemic heart disease--a multi-center study.

Authors:  S Hoka; J Yoshitake; K Dan; Y Goto; N Honda; T Morioka; T Muteki; Y Okuda; A Shigematsu; M Takasaki; T Totoki; N Yoshimura
Journal:  J Anesth       Date:  1993-04       Impact factor: 2.078

10.  Prostaglandin E1 (PGE1) attenuates vasoconstriction induced by PGE2, PGD2 and phorbol myristate acetate in the perfused rat liver.

Authors:  H Inaba; M Araki; T Numai; T Mizuguchi
Journal:  J Anesth       Date:  1993-01       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.